NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors […]

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=160666&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE:EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ:EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/petco-lawsuit-submission-form?prid=160648&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=160647&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ZEEKR Intelligent Technology Holding Limited ("Zeekr" or the "Company") (NYSE:ZK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zeekr and certain of its officers

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=160646&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or